Real‐world experience of sequential treatment of afatinib and osimertinib (RESET) is the first multicenter study in South Korea in patients with EGFR‐mutated advanced NSCLC, comprehensively comparing the RWD of sequential treatment with afatinib and osimertinib to the RWD of other second‐line treatments. Here, EGFR is linked to non-small cell lung carcinoma.